SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of \[225Ac\]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or metastatic solid tumors. Phase 1 will identify the recommended dose through dose escalation, followed by a randomized comparison of two candidate dosing regimens (dose optimization). In Phase 2, the selected dose will be tested in independent cohorts by tumor type.

Trial Details

NCT ID
NCT07873450
Phase
PHASE1 / PHASE2
Sponsor
Full-Life Technologies UK Limited
Status
RECRUITING
Cancer Type
Squamous Cell Lung Cancer
Interventions
  • [225Ac]Ac-FL-261
Locations (sample)
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Nedlands, Australia|-31.98184,115.8073
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • They have signed the consent form before any study-related tests or procedures are done and are willing to follow all study requirements.
  • They are 18 years of age or older.
  • They have a confirmed diagnosis of an advanced or metastatic cancer that cannot be cured with surgery, radiation, or other treatments.
  • Phase 1: Non-squamous non-small cell lung cancer (ns-NSCLC).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Lung Cancer Trials on Trialify →